1.Overview of new veterinary drugs
Registration Classification:> Class II
New veterinary drug registration certificate number:
Tidiluoxin: (2021) New Veterinary Drug Certificate No. 23
Tidiluoxin Injection: (2021) New Animal Medicine No. 24
Main ingredient: Tidiluoxin
Role and use: Macrolide antibiotics. It is used for the treatment of swine respiratory diseases caused by Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis that are sensitive to Tediroxine.
Usage and Dosage: Based on Taidiluoxin. Intramuscular injection: One dose, 4mg per 1kg body weight, pigs (equivalent to 1ml injection of this product per 10kg body weight), use only once.
2.Mechanism of action
Tadilosin is a 16-membered cyclohexanide antibiotic dedicated to semisynthetic animals, and its antibacterial effect is similar to that of tylosin, which mainly prevents peptide chain elongation and inhibits the synthesis of bacterial proteins by binding to the 50S subunit of the bacterial ribosome. It has a wide antibacterial spectrum and has a bacteriostatic effect on both positive and some negative bacteria, especially sensitive to respiratory pathogens, such as Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Streptococcus suis.
At present, the primary problem facing the livestock breeding industry worldwide is the high morbidity and mortality of respiratory diseases, with economic losses caused by respiratory diseases as high as hundreds of millions of yuan per year. Tadiluoxin injection can provide the whole course of treatment for the prevention and treatment of respiratory infectious diseases caused by sensitive bacteria in pigs, and has a very obvious therapeutic effect on respiratory diseases in pigs. It has many advantages such as special animal use, less dosage, the whole course of treatment with one administration, long elimination half-life, high bioavailability and low residue.
3. Significance of successful R&D of new veterinary drugs to Veyong
With the development of the breeding industry in my country, under the conditions of large-scale and high-density breeding, the disease roots are difficult to remove, the pathogens are unclear, and the selection of drugs is not accurate. All of these have led to the intensification of respiratory diseases in pigs, which has become a major development in the pig industry. Difficulties have brought serious harm to animal husbandry, and the prevention and treatment of respiratory diseases has attracted much attention.
In these general contexts, with the acquisition of the new veterinary drug certificate, it is an affirmation of Veyong's continuous technological innovation, increased R&D investment, and emphasis on the introduction of talents. It is in line with the company's positioning of respiratory experts, intestinal experts, and deworming experts. It is consistent that this product is currently an important product for the prevention and treatment of respiratory diseases in pigs. It is believed that it will become another explosive product after the star product of Veyong's respiratory tract in the future! It is of great significance to enhance the company's market competitiveness and consolidate the company's position as a respiratory expert.
Post time: May-15-2021
.png)
.png)
.png)
.png)